BTIG analyst Marie Thibault downgraded Pear Therapeutics to Neutral from Buy without a price target after the company announced it is exploring strategic alternatives to maximize shareholder value. With the shares trading at a "depressed valuation," any potential sale might be transacted at a "steep discount to a fair revenue-based valuation," the analyst tells investors in a research note. The process to explore strategic alternatives leaves the firm "less optimistic" that Pear’s value will be properly recognized.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PEAR:
